首页|改进核酸筛查混检阳性池再检模式的探讨

改进核酸筛查混检阳性池再检模式的探讨

扫码查看
目的 通过分析核酸筛查混检阳性池CT值分布区间与拆分率的相关性,为改进混检阳性池再检模式,降低输血残余风险提供依据。方法 回顾性分析2017年1月—2021年12月本站Cobas S201检测系统核酸筛查HBV混检阳性池标本拆分情况,选取影响拆分成功的主要因素CT值,以CT值分布区间为依据制定再检实验方案。针对2022年3月—2023年3月HBV混检阳性池标本,进行Cobas S201和Panther检测系统的同步检测,统计分析该类标本检测结果。结果 2017-2021年5年间混检阳性池为474个,混检HBV阳性池为324个,占混检阳性池的68。35%,其中2017-2020年每年的HBV阳性池占比明显高于HCV和HIV阳性池(P<0。05);5年间HBV拆分阳性池为167个,占混检HBV阳性池的51。54%,拆分阴性池为157个,占混检HBV阳性池的48。46%。5年间HBV拆分阳性池按CT值分为3个区间:CT值≤36、36<CT值≤40和CT值>40,其拆分率分别为95。8%、56。5%和14。8%(P<0。05);拆分阳性和拆分阴性2组中,36<CT值≤40区间混检池数量占比最高分别为80。8%、66。2%,且与其它2区间比较有差异(P<0。05)。2022年3月—2023年3月混检HBV阳性池有65个,CT值≤36区间(5个)和CT值>40区间(12个),经Cobas S201拆分和Panther联检符合率都为100%,36<CT值≤40区间(48个),2种检测方法的符合率为81。25%。Cobas S201首次拆分结果和Panther联检结果不一致有9份标本,有4份标本Cobas S201首次拆分是阴性,同步Panther联检是阳性,4份标本中3份Cobas S201再单检是阳性,1份Cobas S201再单检是阴性,按照制定的再检方案判定规则是9份标本判定为不合格,按照混检阳性池拆分1次阴性即放行的规则至少会有3份标本漏检。结论 核酸筛查中混检阳性池再拆分阴性的献血者标本占有一定的比例,混检阳性池拆分1次阴性即放行的规则有漏检风险,对这部分标本可以有选择性的(36<CT值≤40区间)进行再检判定结果,既保证了血液安全又节约了再检成本。
Retest improvement for minipool nucleic acid testing positive samples
Objective To analyze the correlation between the distribution interval of minipool nucleic acid testing(NAT)positive CT value and the resolution rate,so as to improve the retest model and reduce residual risk of blood transfu-sion.Methods The resolution testing results by Cobas S201 system of our blood center from January 2017 to December 2021 were retrospective analyzed,and the retest model was developed based on the distribution interval of CT values.For minipool NAT HBV positive samples from March 2022 to March 2023,synchronous detection was conducted by Cobas S201 and Panther detection system,and the detection results were statistically analyzed.Results From 2017 to 2021,474 were minipool NAT positive,among which 324 were HBV positive,accounting for 68.35%.From 2017 to 2020,the proportion of HBV positive per year was significantly higher than that of HCV and HIV(P<0.05).In resolution testing,167 were HBV repeatable positive and 157 were HBV non-repeatable positive,accounting for 51.54%and 48.46%of HBV minipool NAT positive.HBV repeatable positive samples were with three intervals:CT value ≤ 36,36<CT value ≤ 40 and CT value>40,with the resolution rate at 95.8%,56.5%and 14.8%respectively(P<0.05).The proportion of 36<CT value≤40 interval in resolution positive group and resolution negative group was 80.8%and 66.2%respectively,and showed statistical differences compared with other two intervals(P<0.05).From March 2022 to March 2023,65 were HBV positive in minipool NAT,with 5,12,and 48 in CT value ≤36,CT value>40,36<CT value≤40 intervals respectively,with the concordance rate at 100%,100%,and 81.25%by Cobas S201 and Panther detcetion.Nine samples presented inconsistent results:4 samples were resolution negative by Cobas S201 but positve by Panther,3 were repeatable positive and 1 was non-repeatable positive by Cobas S201.These 9 samples were seen as unqualified,but according to original rules(non-repeatable positive samples were seen as qualified),missed detection of at least 3 samples might occur.Conclusion There was a certain proportion of non-repeatable positive samples in positive pool,and the rules(non-repeatable positive samples were seen as qualified)have a risk of missed detection.Those with 36<CT value ≤40 interval should be rested to ensure blood safety and save res-test cost.

hepatitis B virus(HBV)nucleic acid testing(NAT)minipool testingresidual risk

侯云、冯秋霞、李蓓、张龙穆、杨忠思、焦淑贤

展开 >

青岛市中心血站,山东青岛 266071

乙型肝炎病毒 核酸检测 混样检测 残余风险

中国输血协会圣湘基金

CSBT-SX-2022-03

2024

中国输血杂志
中国输血协会 中国医学科学院输血研究所

中国输血杂志

CSTPCD
影响因子:1.279
ISSN:1004-549X
年,卷(期):2024.37(2)
  • 21